Return On Equity
-215%
Third-party reference; reporting period not verified
Period Q3 2026 · Filed 28 Oct 2026
Return On Equity
-215%
Third-party reference; reporting period not verified
Return On Assets
-100%
Third-party reference; reporting period not verified
Operating Margin
0%
Third-party reference; reporting period not verified
Current Ratio
2.76x
Third-party reference; reporting period not verified
Quick Ratio
2.57x
Third-party reference; reporting period not verified
NetIncomeLoss YoY
-33%
Trailing 12 months · Through 31 Jul 2026
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-215%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
-100%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
0%
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
2.76x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
2.57x
Third-party reference; reporting period not verified
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| NetIncomeLoss YoY |
-33%
Trailing 12 months · 31 Jul 2026
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
8,732,381
Period-end balance · 28 Oct 2026
|
+364% |
| Common Stock, Shares, Outstanding |
8,708,029
Period-end balance · 31 Jul 2026
|
+362% |
| Common Stock, Value, Issued |
$120,914,482
Period-end balance · 31 Jul 2026
|
+19% |
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
-$138,684
Period-end balance · 31 Jul 2026
|
0% |
| Assets |
$23,579,729
Period-end balance · 31 Jul 2026
|
+8.9% |
| Assets, Current |
$22,044,940
Period-end balance · 31 Jul 2026
|
+11% |
| Cash and Cash Equivalents, at Carrying Value |
$9,852,435
Period-end balance · 31 Jul 2026
|
-6.1% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$9,852,435
Period-end balance · 31 Jul 2026
|
-6.1% |
| Common Stock, Shares, Issued |
8,708,029
Period-end balance · 31 Jul 2026
|
+362% |
| Deferred Tax Assets, Gross |
$35,381,810
Period-end balance · 31 Jul 2026
|
+24% |
| Deferred Tax Assets, Net of Valuation Allowance |
$306,681
Period-end balance · 31 Jul 2026
|
-93% |
| Deferred Tax Assets, Operating Loss Carryforwards |
$14,921,914
Period-end balance · 31 Jul 2026
|
+76% |
| Deferred Tax Assets, Valuation Allowance |
$35,075,129
Period-end balance · 31 Jul 2026
|
+44% |
| Earnings Per Share, Basic |
-6.97
Trailing 12 months · 31 Jul 2026
|
+89% |
| Earnings Per Share, Diluted |
-6.97
Trailing 12 months · 31 Jul 2026
|
+89% |
| General and Administrative Expense |
$6,817,729
Trailing 12 months · 31 Jul 2026
|
+15% |
| Intangible Assets, Net (Excluding Goodwill) |
$169,254
Period-end balance · 31 Jul 2026
|
-8.3% |
| Liabilities and Equity |
$23,579,729
Period-end balance · 31 Jul 2026
|
+8.9% |
| Liabilities, Current |
$7,981,648
Period-end balance · 31 Jul 2026
|
+101% |
| Nonoperating Income (Expense) |
$601,461
Trailing 12 months · 31 Jul 2026
|
+425% |
| Operating Income (Loss) |
-$36,054,237
Trailing 12 months · 31 Jul 2026
|
-33% |
| Property, Plant and Equipment, Net |
$319,804
Period-end balance · 31 Jul 2026
|
+7.7% |
| Research and Development Expense |
$29,236,508
Trailing 12 months · 31 Jul 2026
|
+37% |
| Retained Earnings (Accumulated Deficit) |
-$146,659,826
Period-end balance · 31 Jul 2026
|
-31% |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
$15,559,142
Period-end balance · 31 Jul 2026
|
-10% |
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q2 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
28 Oct 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 28 Oct 2026.
Benchmark Context
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with BriaCell Therapeutics Corp.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-10-28) highlights Return On Equity -214.8%, Return On Assets -99.6%, and Operating Margin 0.0%.
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Fair value per share
n/a
Market price
$3.31
BCTX - Local security
PEG ratio
n/a
Enterprise value
-$419.11M
Equity value
n/a
Bear
n/a
Base
n/a
Bull
n/a
Base growth: DCF Growth Assumption.
EV/Revenue
n/a
Local security market EV / SEC revenue
Market enterprise value is unavailable
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Market enterprise value is unavailable
P/E
n/a
Local security market price / SEC EPS
Net income is unavailable or not positive
P/S
n/a
Local security market cap / SEC revenue
Revenue is unavailable or not positive
P/B
1.1x
Local security market cap / SEC equity
PEG
n/a
P/E / DCF Growth Assumption
P/e or positive growth is unavailable
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
Use these links to compare BCTX - BriaCell Therapeutics Corp. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Latest value: -33%
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
22.3/100
Weak Confidence medium
-215%
Metric score 0.0/100
-100%
Metric score 0.0/100
Current Ratio
Return On Equity, Return On Assets, and Operating Margin
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
CIK / security context first